BioLineRx (BLRX) Commences Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
Tweet Send to a Friend
BioLineRx Ltd. (NASDAQ: BLRX) announced today the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202 study in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
